Life Extension Inc., Fort Lauderdale, Florida, USA.
Biofactors. 2021 Jan;47(1):6-18. doi: 10.1002/biof.1691. Epub 2020 Nov 28.
Specialized proresolving mediators (SPMs) are endogenous lipid metabolites of long-chain polyunsaturated fatty acids that are involved in promoting the resolution of inflammation. Many disease conditions characterized by excessive inflammation have impaired or altered SPM biosynthesis, which may lead to chronic, unresolved inflammation. Exogenous administration of SPMs in infectious conditions has been shown to be effective at improving infection clearance and survival in preclinical models. SPMs have also shown tremendous promise in the context of inflammatory lung conditions, such as acute respiratory distress syndrome and chronic obstructive pulmonary disease, mostly in preclinical settings. To date, SPMs have not been studied in the context of the novel Coronavirus, severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), however their preclinical efficacy in combatting infections and improving acute respiratory distress suggest they may be a valuable resource in the fight against Coronavirus disease-19 (COVID-19). Overall, while the research on SPMs is still evolving, they may offer a novel therapeutic option for inflammatory conditions.
特异性促炎消退介质（SPM）是长链多不饱和脂肪酸的内源性脂质代谢物，参与促进炎症消退。许多以过度炎症为特征的疾病状态存在 SPM 生物合成受损或改变，这可能导致慢性、未解决的炎症。在感染性疾病中，外源性给予 SPM 已被证明可有效改善临床前模型中的感染清除率和存活率。SPM 在炎症性肺部疾病（如急性呼吸窘迫综合征和慢性阻塞性肺疾病）中也显示出巨大的潜力，主要是在临床前环境中。迄今为止，尚未在新型冠状病毒、严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的背景下研究 SPM，但它们在对抗感染和改善急性呼吸窘迫方面的临床前疗效表明，它们可能是对抗冠状病毒病-19（COVID-19）的有价值资源。总的来说，虽然 SPM 的研究仍在不断发展，但它们可能为炎症性疾病提供一种新的治疗选择。
